|Bid||66.50 x 900|
|Ask||66.84 x 900|
|Day's Range||61.06 - 67.16|
|52 Week Range||42.51 - 169.76|
|Beta (5Y Monthly)||2.01|
|PE Ratio (TTM)||12.72|
|Earnings Date||Apr 25, 2022 - Apr 29, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||121.86|
Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.
Yahoo Finance's Jared Blikre checks out the market and sector action heading into today's close, software stocks, ARK ETF components, and the travel industry ahead of the close.
CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.